Choosing the Appropriate Treatment in the Second Line Setting in SCLC
Experts provide insights on choosing the optimal therapy in patients with small cell lung cancer in the second line and beyond.
EP: 1.Overview of SCLC and Importance of Early Diagnosis
EP: 2.Use of the TNM Staging System in SCLC
EP: 3.Progress in the Treatment and Management of SCLC
EP: 4.Patient Profile 1: A 68-Year-Old Male with SCLC and Brain Metastases
EP: 5.Frontline Therapy for SCLC: The CASPIAN Trial of Durvalumab + Chemotherapy
EP: 6.Management of Adverse Events Associated with Durvalumab + Chemotherapy
EP: 7.IMpower 133 Trial and Patient Selection for Durvalumab + Chemotherapy vs Atezolizumab + Chemotherapy
EP: 8.Ongoing Trials and Real-World Studies in Frontline SCLC
EP: 9.Patient Profile 2: A 60-Year-Old Man with SCLC Progressing on First-Line Therapy
EP: 10.Second Line Treatment Options in SCLC and Selecting the Appropriate Therapy
EP: 11.Lurbinectedin for SCLC Treatment in the Second-Line Setting
EP: 12.Patient Profile 3: A 70-Year-Old Man with SCLC Receiving Chemotherapy in the Second-Line Setting
Now Viewing
EP: 13.Choosing the Appropriate Treatment in the Second Line Setting in SCLC
EP: 14.Investigational Agents in SCLC in the Second Line Setting and Beyond
EP: 15.Clinical Practice Pearls and the Future of SCLC
Related Videos
Related Content
